Search

Brensocatib

[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813]

Mepyramine

Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination produc...

Acalabrutinib

Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. … As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules).

DL-alpha tocopheryl acetate

Pancrelipase amylase

[L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

Salmeterol

[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]

Panobinostat

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.

Nandrolone decanoate

[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564]

Brigatinib

[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

Liraglutide

[A6932] Liraglutide was granted FDA approval on January 25, 2010.[L6070]